Tags

Type your tag names separated by a space and hit enter

Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk.
Breast Cancer Res Treat. 2004 Apr; 84(3):225-33.BC

Abstract

The insulin-like growth factor (IGF)-system plays a role in breast cancer susceptibility as well as in growth and progression of breast carcinomas. So far, findings have been based on serum IGF-I levels and semi-quantitative assessment of IGF-system expression levels in model systems and human tissue. Quantitative data on mRNA expression in different types of human breast tissue are lacking. Breast tissue samples (n = 83) were available from 72 women. Messenger RNA expression of IGF-I, IGF-II, and their receptors (IGF-1R and IGF-2R) was assessed by real-time RT-PCR. We found a large variation in mRNA levels. Expression of each gene was significantly higher in normal tissue than in tumor tissue (median for normal and tumor tissue, respectively (arbitrary units); IGF-I: 25.2 and 1.4; IGF-II: 5.9 and 0.6; IGF-1R: 0.18 and 0.07; IGF-2R: 1.8 and 0.9; p < 0.0001, Mann-Whitney test). Interestingly, in tumor tissue from patients with a strong family history of breast cancer, expression of both receptors was higher than in sporadic patients (IGF-1R: 0.13 and 0.05, p = 0.04; IGF-2R: 1.1 and 0.8, p = 0.04). For cancer-free controls, expression of IGF-II and IGF-2R in normal breast tissue was also higher in women with a family history of breast cancer than in women without such a family history (IGF-II: 7.2 and 1.5, p = 0.02; IGF-2R: 2.6 and 1.5, p = 0.09). Our study quantitatively shows that mRNA expression levels of IGF-system components in the breast are generally higher in normal tissue compared with tumor tissue, and higher in tissue from women with a family history of breast cancer. A basis has therefore been created for studies aimed at understanding IGF as a breast cancer risk factor, the relationship between IGF-systems in serum and tissues, and effects of lifestyle factors on the IGF-system.

Authors+Show Affiliations

Division of Experimental Therapy, The Netherlands Cancer Institute, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15026620

Citation

Voskuil, Dorien W., et al. "Insulin-like Growth Factor (IGF)-system mRNA Quantities in Normal and Tumor Breast Tissue of Women With Sporadic and Familial Breast Cancer Risk." Breast Cancer Research and Treatment, vol. 84, no. 3, 2004, pp. 225-33.
Voskuil DW, Bosma A, Vrieling A, et al. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat. 2004;84(3):225-33.
Voskuil, D. W., Bosma, A., Vrieling, A., Rookus, M. A., & van 't Veer, L. J. (2004). Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Research and Treatment, 84(3), 225-33.
Voskuil DW, et al. Insulin-like Growth Factor (IGF)-system mRNA Quantities in Normal and Tumor Breast Tissue of Women With Sporadic and Familial Breast Cancer Risk. Breast Cancer Res Treat. 2004;84(3):225-33. PubMed PMID: 15026620.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. AU - Voskuil,Dorien W, AU - Bosma,Astrid, AU - Vrieling,Alina, AU - Rookus,Matti A, AU - van 't Veer,Laura J, PY - 2004/3/18/pubmed PY - 2004/6/30/medline PY - 2004/3/18/entrez SP - 225 EP - 33 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 84 IS - 3 N2 - The insulin-like growth factor (IGF)-system plays a role in breast cancer susceptibility as well as in growth and progression of breast carcinomas. So far, findings have been based on serum IGF-I levels and semi-quantitative assessment of IGF-system expression levels in model systems and human tissue. Quantitative data on mRNA expression in different types of human breast tissue are lacking. Breast tissue samples (n = 83) were available from 72 women. Messenger RNA expression of IGF-I, IGF-II, and their receptors (IGF-1R and IGF-2R) was assessed by real-time RT-PCR. We found a large variation in mRNA levels. Expression of each gene was significantly higher in normal tissue than in tumor tissue (median for normal and tumor tissue, respectively (arbitrary units); IGF-I: 25.2 and 1.4; IGF-II: 5.9 and 0.6; IGF-1R: 0.18 and 0.07; IGF-2R: 1.8 and 0.9; p < 0.0001, Mann-Whitney test). Interestingly, in tumor tissue from patients with a strong family history of breast cancer, expression of both receptors was higher than in sporadic patients (IGF-1R: 0.13 and 0.05, p = 0.04; IGF-2R: 1.1 and 0.8, p = 0.04). For cancer-free controls, expression of IGF-II and IGF-2R in normal breast tissue was also higher in women with a family history of breast cancer than in women without such a family history (IGF-II: 7.2 and 1.5, p = 0.02; IGF-2R: 2.6 and 1.5, p = 0.09). Our study quantitatively shows that mRNA expression levels of IGF-system components in the breast are generally higher in normal tissue compared with tumor tissue, and higher in tissue from women with a family history of breast cancer. A basis has therefore been created for studies aimed at understanding IGF as a breast cancer risk factor, the relationship between IGF-systems in serum and tissues, and effects of lifestyle factors on the IGF-system. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/15026620/Insulin_like_growth_factor__IGF__system_mRNA_quantities_in_normal_and_tumor_breast_tissue_of_women_with_sporadic_and_familial_breast_cancer_risk_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=15026620.ui DB - PRIME DP - Unbound Medicine ER -